A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

NCT01785771 · Terminated

Last updated 2026-05-28

This clinical trial tested ITCA 650, a potential treatment for type 2 diabetes, in adults with high baseline HbA1c levels to see how it affects blood sugar control over time.

Status Terminated Stopped early and will not restart.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 100 people Planned (estimated).

Who can join Ages 18–80 · all sexes

Timeline Started 2013-05 · est. completion 2018-01

Where 51 sites · United States

What this study is testing ClinicalTrials.gov NCT01785771 ↗

Description as written by the study sponsor.

An 39-week plus extensions, open-label study to estimate the reduction in HbA1c in patients with initial HbA1c \>10% \</=12% who are treated with ITCA 650 20 mcg/day for 13 weeks followed by ITCA 650 60 mcg/day for 26 weeks plus optional 26-week extensions with continued treatment with ITCA 650 60 mcg/day

Treatments tested

ITCA 650 (exenatide in DUROS) Drug

Main thing measured	Change in HbA1c between Week 39 and Day 0
Sponsor	Intarcia Therapeutics
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01785771 ↗